Korean J Dermatol.  2008 Jun;46(6):862-865.

Two Cases of Acneiform Eruption Caused by Epidermal Growth Factor Receptor Inhibitors

• Choi KW
• Lee CY
• Lee YK
• Kim HS
• Kim KH
• Kim YH

Abstract

Epidermal growth factor receptor (EGFR) inhibitors are associated with unique and dramatical dermatological side effects. The most commonly encountered adverse effect is a mild skin toxicity characterized by a sterile follicular and pustular rash that may be treated empirically and usually does not require treatment modification. Secondary adverse reactions seen with anti-EGFR therapy include xerosis, pruritus, paronychia, hair abnormality, and mucositis. According to the Korean literature, there are no reports of acneiform eruption induced by erlotinib (Tarceva(R)). We report a case of acneiform eruption induced by cetuximab (Erbitux(R)) and a case of acneiform eruption induced by erlotinib (Tarceva(R)).

Keyword

Cetuximab; Epidermal growth factor receptor inhibitor; Erlotinib

MeSH Terms

Acneiform Eruptions
Antibodies, Monoclonal, Humanized
Epidermal Growth Factor
Exanthema
Hair
Mucositis
Paronychia
Pruritus
Quinazolines
Receptor, Epidermal Growth Factor
Skin
Cetuximab
Erlotinib Hydrochloride
Antibodies, Monoclonal, Humanized
Epidermal Growth Factor
Quinazolines
Receptor, Epidermal Growth Factor